{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:36:08Z","timestamp":1793921768992,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Young Scientific Research Fund (The Affiliated Hospital of Qingdao University)","award":["20141201"],"award-info":[{"award-number":["20141201"]}],"id":[{"id":"https:\/\/ror.org\/026e9yy16","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Qingdao Science and Technology Project","award":["2008KZJ-13"],"award-info":[{"award-number":["2008KZJ-13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12967-016-0910-0","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T19:39:28Z","timestamp":1464723568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Mingjun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guirong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,1]]},"reference":[{"key":"910_CR1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.20132","volume":"62","author":"JM Kirkwood","year":"2012","unstructured":"Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309\u201335.","journal-title":"CA Cancer J Clin."},{"key":"910_CR2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.20112275","volume":"209","author":"D Pardoll","year":"2012","unstructured":"Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med. 2012;209:201\u20139.","journal-title":"J Exp Med"},{"key":"910_CR3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-065X.2008.00604.x","volume":"222","author":"MA Cheever","year":"2008","unstructured":"Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev. 2008;222:357\u201368.","journal-title":"Immunol Rev"},{"key":"910_CR4","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1158\/1078-0432.CCR-05-2503","volume":"12","author":"MB Atkins","year":"2006","unstructured":"Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res. 2006;12:2353\u20138.","journal-title":"Clin Cancer Res"},{"key":"910_CR5","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1001\/jama.1986.03380220083027","volume":"256","author":"MT Lotze","year":"1986","unstructured":"Lotze MT, Chang AE, Seipp CA, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity and histologic findings. JAMA. 1986;256:3117\u201324.","journal-title":"JAMA"},{"key":"910_CR6","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1200\/JCO.2000.18.9.1954","volume":"18","author":"KR Lindsey","year":"2000","unstructured":"Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol. 2000;18:1954\u20139.","journal-title":"J Clin Oncol"},{"key":"910_CR7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01741084","volume":"36","author":"RA Maas","year":"1993","unstructured":"Maas RA, Dullens HF, Den Otter W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother. 1993;36:141\u20138.","journal-title":"Cancer Immunol Immunother"},{"key":"910_CR8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/81199","volume":"6","author":"AB Shanafelt","year":"2000","unstructured":"Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, Carter C, et al. A T-cell-selective interleukin-2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol. 2000;6:1197\u2013202.","journal-title":"Nat Biotechnol"},{"key":"910_CR9","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1016\/S0021-9258(18)45635-9","volume":"262","author":"G Ju","year":"1987","unstructured":"Ju G, Collins L, Kaffka KL, Tsien WH, Chizzonite R, Crowl R, et al. Simpson, structure-function analysis of human interleukin-2. Identification of amino acid residues required for biological activity. J Biol Chem. 1987;262:5723\u201331.","journal-title":"J Biol Chem"},{"key":"910_CR10","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.2174\/092986610792231474","volume":"17","author":"M Liu","year":"2010","unstructured":"Liu M, Wang B, Gun S, Qian D, Yan Z, Song X, et al. Expression, purification and characterization of a functional mutant recombinant human interleukin-2. Protein Pept Lett. 2010;17:1280\u20134.","journal-title":"Protein Pept Lett"},{"key":"910_CR11","first-page":"194","volume":"27","author":"KA Margolin","year":"2000","unstructured":"Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol. 2000;27:194\u2013203.","journal-title":"Semin Oncol"},{"key":"910_CR12","first-page":"24","volume":"16","author":"X Zhu","year":"2000","unstructured":"Zhu X, Wang J, Wang R, et al. Immunomodulatory effects of bee venom on S180 sarcoma mice. Pharmacol Clin Chin Materia Medica. 2000;16:24\u20135.","journal-title":"Pharmacol Clin Chin Materia Medica"},{"key":"910_CR13","first-page":"542","volume":"16","author":"Q Wang","year":"2000","unstructured":"Wang Q, Lu Y, Zang Y, Huang C, Meng X, Wu B, et al. Study on the immune regulating mechanism of the bee venom. Chin J Immunol. 2000;16:542\u20134.","journal-title":"Chin J Immunol"},{"key":"910_CR14","first-page":"163","volume":"24","author":"L Liu","year":"2003","unstructured":"Liu L, Ling C, Huang X. Study on purification of melittin and its effect on anti-tumor in vitro. Chin J Biochem Pharm. 2003;24:163\u20136.","journal-title":"Chin J Biochem Pharm"},{"key":"910_CR15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.taap.2011.10.009","volume":"258","author":"M Jo","year":"2012","unstructured":"Jo M, Park MH, Kollipara PS, An BJ, Song HS, Han SB, et al. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2\/STAT3 pathway. Toxicol Appl Pharmacol. 2012;258:72\u201381.","journal-title":"Toxicol Appl Pharmacol"},{"key":"910_CR16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0041-0101(99)00110-5","volume":"37","author":"SS Saini","year":"1999","unstructured":"Saini SS, Chopra AK, Peterson JW. Melittin activates endogenous phospholipase D during cytolysis of human monocytic leukemia cells. Toxicon. 1999;37:1605\u201319.","journal-title":"Toxicon"},{"key":"910_CR17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/(SICI)1097-4652(199606)167:3<434::AID-JCP7>3.0.CO;2-Q","volume":"167","author":"AS Arora","year":"1996","unstructured":"Arora AS, de Groen PC, Croall DE, Emori Y, Gores GJ. Hepatocellular carcinoma cells resist necrosis during anoxia by preventing phospholipase-mediated calpain activation. J Cell Physiol. 1996;167:434\u201342.","journal-title":"J Cell Physiol"},{"key":"910_CR18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000024154","volume":"118","author":"H Kubo","year":"1999","unstructured":"Kubo H, Loegering DA, Adophson CR, Emori Y, Gores GJ. Cytotoxic properties of eosinophil granule major basic protein for tumor cells. Int Arch Allergy Immunol. 1999;118:426\u20138.","journal-title":"Int Arch Allergy Immunol"},{"key":"910_CR19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0924-8579(01)00479-4","volume":"19","author":"VN Lazarev","year":"2002","unstructured":"Lazarev VN, Parfenova TM, Gularyan SK, Misyurina OY, Akopian TA, Govorun VM. Induced expression of melittin, an antimicrobial peptide, inhibits infection by Chlamydia trachomatis and Mycoplasma hominis in a hela cell line. Int J Antimicrob Agents. 2002;19:133\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"910_CR20","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00262-013-1401-2","volume":"62","author":"M Liu","year":"2013","unstructured":"Liu M, Zong J, Liu Z, Li L, Zheng X, Wang B, et al. A novel melittin-MhIL-2 fusion protein inhibits the growth of human ovarian cancer SKOV3 cells in vitro and in vivo tumor growth. Cancer Immunol Immunother. 2013;62:889\u201395.","journal-title":"Cancer Immunol Immunother"},{"key":"910_CR21","first-page":"884","volume":"61","author":"YI Son","year":"2001","unstructured":"Son YI, Dallal RM, Mailliard RB, Egawa S, Jonak ZL, Lotze MT. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production and expansion of natural killer cells. Cancer Res. 2001;61:884\u20138.","journal-title":"Cancer Res"},{"key":"910_CR22","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1139\/o2012-030","volume":"90","author":"C Li","year":"2012","unstructured":"Li C, Qi Q, Lu N, Dai Q, Li F, Wang X, You Q, Guo Q. Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol. 2012;90:718\u201330.","journal-title":"Biochem Cell Biol"},{"key":"910_CR23","doi-asserted-by":"crossref","first-page":"9385","DOI":"10.1073\/pnas.0900108106","volume":"106","author":"X Lu","year":"2009","unstructured":"Lu X, Kang Y. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc Natl Acad Sci USA. 2009;106:9385\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"910_CR24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1749-6632.2001.tb03720.x","volume":"941","author":"FM Foss","year":"2001","unstructured":"Foss FM. Interleukin-2 fusion toxin: targeted therapy for coetaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941:166\u201376.","journal-title":"Ann N Y Acad Sci"},{"key":"910_CR25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0190-9622(98)70403-7","volume":"39","author":"MN Saleh","year":"1998","unstructured":"Saleh MN, LcMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G, et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998;39:63\u201373.","journal-title":"J Am Acad Dermatol"},{"key":"910_CR26","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3892\/ijo.2015.3078","volume":"47","author":"D Wang","year":"2015","unstructured":"Wang D, Hu L, Su M, Wang J, Xu T. Preparation and functional characterization of human vascular endothelial growth factor-melittin fusion protein with analysis of the antitumor activity in vitro and in vivo. Int J Oncol. 2015;47:1160\u20138.","journal-title":"Int J Oncol"},{"key":"910_CR27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4049\/jimmunol.143.1.15","volume":"143","author":"TF Gajewski","year":"1989","unstructured":"Gajewski TF, Joyce J, Fitch FW. Antiproliferative effect of IFN-\u03b3 in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-\u03b3. J Immunol. 1989;143:15\u201322.","journal-title":"J Immunol"},{"key":"910_CR28","first-page":"491","volume-title":"The cytokine handbook","author":"E Maeyer De","year":"1998","unstructured":"De Maeyer E, De Maeyer-Guignard J. Interferons. In: Thomson A, editor. The cytokine handbook. 3rd ed. San Diego CA: Academic Press; 1998. p. 491\u2013516.","edition":"3"},{"key":"910_CR29","first-page":"73","volume-title":"The cytokine handbook","author":"SL Gaffen","year":"1998","unstructured":"Gaffen SL, Goldsmith MA, Greene WC. Interleukin-2 and interleukin-2 receptor. In: Thomson A, editor. The cytokine handbook. 3rd ed. San Diego. CA: Academic Press; 1998. p. 73\u2013103.","edition":"3"},{"key":"910_CR30","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/IAI.57.2.590-595.1989","volume":"57","author":"K Nakamura","year":"1989","unstructured":"Nakamura K, Okamura H, Wada M, Nagata K, Tamura T. Endotoxin induced serum factor that stimulates gamma interferon production. Infect Immun. 1989;57:590\u20135.","journal-title":"Infect Immun"},{"key":"910_CR31","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.4049\/jimmunol.158.4.1541","volume":"158","author":"K Kohno","year":"1997","unstructured":"Kohno K, Kataoka J, Ohtsuki T, Suemoto Y, Okamoto I, Usui M, et al. IFN-\u03b3-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol. 1997;158:1541\u201350.","journal-title":"J Immunol"},{"key":"910_CR32","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1074\/jbc.M807191200","volume":"284","author":"C Wang","year":"2009","unstructured":"Wang C, Chen T, Zhang N, Yang M, Li B, L\u00fc X, et al. Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating caMKII-TAK1-JNK\/p38 and inhibiting I\u03baB\u03b1 kinase-NF\u03baB. J Biol Chem. 2009;284:3804\u201313.","journal-title":"J Biol Chem"},{"key":"910_CR33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10059-010-0028-9","volume":"29","author":"JH Park","year":"2010","unstructured":"Park JH, Jeong YJ, Park KK, Cho HJ, Chung IK, Min KS, et al. Melittin suppresses PMA-induced tumor cell invasion by inhibiting NF-kappaB and AP-1-dependent MMP-9 expression. Mol Cells. 2010;29:209\u201315.","journal-title":"Mol Cells"},{"key":"910_CR34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/pros.21296","volume":"71","author":"MH Park","year":"2011","unstructured":"Park MH, Choi MS, Kwak DH, Oh KW, Yoon do Y, Han SB, et al. Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-\u039aB. Prostate. 2011;71:801\u201312.","journal-title":"Prostate"},{"key":"910_CR35","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/hep.22240","volume":"47","author":"S Liu","year":"2008","unstructured":"Liu S, Yu M, He Y, Wang F, Song C, Sun S, et al. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology. 2008;47:1964\u201373.","journal-title":"Hepatology"},{"key":"910_CR36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","volume":"316","author":"SA Rosenberg","year":"1987","unstructured":"Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889\u201397.","journal-title":"N Engl J Med"},{"key":"910_CR37","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1084\/jem.155.6.1823","volume":"155","author":"EA Grimm","year":"1982","unstructured":"Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823\u201341.","journal-title":"J Exp Med"},{"key":"910_CR38","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1021\/nn400683s","volume":"7","author":"C Huang","year":"2013","unstructured":"Huang C, Jin H, Qian Y, Qi S, Luo H, Luo Q, et al. Hybrid melittin cytolytic Peptide-driven ultrasmall lipid nanoparticles block melanoma growth in vivo. ACS Nano. 2013;7:5791\u2013800.","journal-title":"ACS Nano"},{"key":"910_CR39","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1021\/np300446c","volume":"75","author":"JE Huh","year":"2012","unstructured":"Huh JE, Kang JW, Nam D, Baek YH, Choi DY, Park DS, et al. Melittin suppresses VEGF-A-induced tumor growth by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway. J Nat Prod. 2012;75:1922\u20139.","journal-title":"J Nat Prod"},{"key":"910_CR40","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1172\/JCI38842","volume":"119","author":"NR Soman","year":"2009","unstructured":"Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, Heuser JE, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest. 2009;119:2830\u201342.","journal-title":"J Clin Invest"},{"key":"910_CR41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gde.2007.12.006","volume":"18","author":"M Hu","year":"2008","unstructured":"Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev. 2008;18:27\u201334.","journal-title":"Curr Opin Genet Dev"},{"issue":"Suppl 1","key":"910_CR42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12307-009-0025-8","volume":"2","author":"IP Witz","year":"2009","unstructured":"Witz IP. The tumor microenvironment: the making of a paradigm. Cancer Microenviron. 2009;2(Suppl 1):9\u201317.","journal-title":"Cancer Microenviron"},{"key":"910_CR43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00280-008-0881-9","volume":"63","author":"F Mbeunkui","year":"2009","unstructured":"Mbeunkui F, Johann DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63:571\u201382.","journal-title":"Cancer Chemother Pharmacol"},{"key":"910_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prp.2009.10.001","volume":"206","author":"N Sengupta","year":"2010","unstructured":"Sengupta N, MacFie TS, MacDonald TT, Pennington D, Silver AR. Cancer immunoediting and spontaneous tumor regression. Pathol Res Pract. 2010;206:1\u20138.","journal-title":"Pathol Res Pract"},{"key":"910_CR45","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4049\/jimmunol.179.3.1568","volume":"179","author":"Z Li","year":"2007","unstructured":"Li Z, Pradera F, Kammertoens T, Li B, Liu S, Qin Z. Cross-talk between T cells and innate immune cells is crucial for IFN-gamma dependent tumor rejection. J Immunol. 2007;179:1568\u201376.","journal-title":"J Immunol"},{"key":"910_CR46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1006\/cimm.1994.1162","volume":"156","author":"PS Goedegebuure","year":"1994","unstructured":"Goedegebuure PS, Lee KY, Matory YL, Peoples GE, Yoshino I, Eberlein TJ. Classification of CD4+ T helper cell clones in human melanoma. Cell Immunol. 1994;156:170\u20139.","journal-title":"Cell Immunol"},{"key":"910_CR47","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/ni1138","volume":"5","author":"A Mart\u00edn-Fontecha","year":"2004","unstructured":"Mart\u00edn-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for t(h)1 priming. Nat Immunol. 2004;5:1260\u20135.","journal-title":"Nat Immunol"},{"key":"910_CR48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin. 2014;64:9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"910_CR49","first-page":"2597","volume":"53","author":"KM Heaton","year":"1993","unstructured":"Heaton KM, Ju G, Grimm EA. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res. 1993;53:2597\u2013602.","journal-title":"Cancer Res"},{"key":"910_CR50","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/1078-0432.CCR-08-1296","volume":"15","author":"HK Jensen","year":"2009","unstructured":"Jensen HK, Donskov F, Nordsmark M, Marcussen N, von der Maase H. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res. 2009;15:1052\u2013508.","journal-title":"Clin Cancer Res"},{"key":"910_CR51","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/08923973.2013.802802","volume":"35","author":"S Rasmussen","year":"2013","unstructured":"Rasmussen S, Donskov F, Pedersen JW, Wandall HH, Buus S, Harndahl M, et al. Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy. Immunopharmacol Immunotoxicol. 2013;35:487\u201396.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"910_CR52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10555-011-9339-3","volume":"31","author":"N Or\u0161oli\u0107","year":"2012","unstructured":"Or\u0161oli\u0107 N. Bee venom in cancer therapy. Cancer Metastasis Rev. 2012;31:173\u201394.","journal-title":"Cancer Metastasis Rev"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-016-0910-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T14:02:02Z","timestamp":1692367322000},"score":1,"resource":{"primary":{"URL":"http:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-016-0910-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["910"],"URL":"https:\/\/doi.org\/10.1186\/s12967-016-0910-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,1]]},"article-number":"155"}}